Stock Detail
KERYX BIOPHARMACEUTICALS INC
Sector: Biotechnology
Latest Quote @ Fri May 5 13:12:42 (15 min delayed)
| $7.99 |
$8.00 |
$7.99 |
-0.04 |
-0.50% |
|
Last Day's Data
| $8.03 |
$8.06 |
$0.15 |
1.90% |
0.00 |
$7.88 |
| $7.78 |
$7.62 |
1.00 |
656.20M |
2.33M |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 8.34 |
8.18 |
7.90 |
7.74 |
7.46 |
Stock Profile
Keryx Biopharmaceuticals, Inc., a development stage company, engages in the acquisition, development, and commercialization of pharmaceutical products for the treatment of diabetes and cancer. The company has two product candidates in the later stages of clinical development, which include sulodexide, or KRX-101, for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes; and perifosine or KRX-0401 for the treatment of multiple forms of cancer. Its other drug portfolio includes three clinical stage oncology compounds, designated as KRX-0402 and KRX-0403. The company has strategic alliances with Alfa Wassermann S.p.A.; Zentaris AG; Opocrin, S.p.A.; Paligent, Inc.; Collaborative Study Group; and Prescient NeuroPharma, Inc. The company was incorporated in 1998 under the name Paramount Pharmaceuticals, Inc. and changed its name to Lakaro Biopharmaceuticals, Inc. in 1999 and to Keryx Biopharmaceuticals, Inc. in 2000. Keryx Biopharmaceuticals is headquartered in New York City.
